Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism

Anticipation centers on a drug that could preserve muscle while promoting fat loss, a combination many view as a missing piece in obesity treatment. Roche secured exclusive rights to Hanmi Pharm’s clinical‑stage obesity candidate through a licensing pact reported as worth up to $2.5 billion, while other outlets cite a $2.3 billion figure. The agreement, signed with Hanmi’s Genentech unit, transfers development and commercial responsibilities to Roche, positioning the Swiss group to expand its metabolic portfolio amid a surge of high‑value Korean biotech deals that could boost its pipeline.

SWI swissinfo.ch noted Roche’s acquisition of the rights, and Fierce Biotech detailed the $2.5 billion pact, describing the asset as “muscle‑sparing” and built on a less‑explored biological pathway. Investing.com reported Hanmi Pharm’s share price jumped 30 percent immediately after the announcement, underscoring market confidence. Endpoints News added that the candidate’s early‑stage muscle‑building profile could differentiate it from existing GLP‑1 agonists, potentially opening a new therapeutic niche.

The next steps hinge on regulatory review and clinical trial outcomes, which have not yet been detailed in the public filings. Observers will watch for Phase II data releases and any FDA or EMA filings that could confirm the timeline for market entry. How quickly the drug can demonstrate muscle preservation alongside effective weight loss will determine whether it reshapes treatment standards or remains a niche offering.